Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Hamby

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Opinion in Biotechnology|December 22, 1999
Antiangiogenic agentsW D Klohs, J M Hamby
Pharmacology & Therapeutics|August 24, 1999
Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitorsJ M Hamby, H D Showalter
Journal of Medicinal Chemistry|June 20, 1998
Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitorsS Trumpp-Kallmeyer, J R Rubin, C Humblet, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1997
Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitorT K Dahring, G H Lu, J M Hamby, et al.
Journal of Medicinal Chemistry|July 1, 1989
Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analoguesE C Taylor, J M Hamby, C Shih, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 10, 1998
In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinaseR L Panek, G H Lu, T K Dahring, et al.
Life Sciences|March 6, 1998
Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitorB L Batley, A M Doherty, J M Hamby, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 12, 1998
In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitorR L Panek, G H Lu, S R Klutchko, et al.
The EMBO Journal|October 17, 1998
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domainM Mohammadi, S Froum, J M Hamby, et al.
Journal of Medicinal Chemistry|August 6, 1993
Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H- imidazole-5-carboxylic acid (CI-996)I Sircar, J C Hodges, J Quin, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Opinion in Biotechnology|December 22, 1999
Antiangiogenic agentsW D Klohs, J M Hamby
Pharmacology & Therapeutics|August 24, 1999
Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitorsJ M Hamby, H D Showalter
Journal of Medicinal Chemistry|June 20, 1998
Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitorsS Trumpp-Kallmeyer, J R Rubin, C Humblet, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1997
Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitorT K Dahring, G H Lu, J M Hamby, et al.
Journal of Medicinal Chemistry|July 1, 1989
Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analoguesE C Taylor, J M Hamby, C Shih, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 10, 1998
In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinaseR L Panek, G H Lu, T K Dahring, et al.
Life Sciences|March 6, 1998
Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitorB L Batley, A M Doherty, J M Hamby, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 12, 1998
In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitorR L Panek, G H Lu, S R Klutchko, et al.
The EMBO Journal|October 17, 1998
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domainM Mohammadi, S Froum, J M Hamby, et al.
Journal of Medicinal Chemistry|August 6, 1993
Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H- imidazole-5-carboxylic acid (CI-996)I Sircar, J C Hodges, J Quin, et al.
Pageof 2